相关临床试验
109
33 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1913
进行中（未招募）
28
25.7%
已完成
54
49.5%
尚未招募
5
4.6%
招募中
1
0.9%
终止
1
0.9%
Unknown
20
18.4%
暂无批准数据
- A University of Exeter study of more than 1,100 insulin-treated patients found a type 1 genetic risk score identified hidden type 1 diabetes in 16% of those with a negative MODY genetic test. - The approach will now be adopted as part of NHS testing, enabling laboratories to provide a diagnosis where results previously returned without explanation. - Researchers say the score reduces the need for expensive further testing and helps clinicians distinguish MODY from type 1 diabetes to target individualized treatment. - The study, published in Diabetes Care, was funded by Diabetes UK and the Medical Research Council and supported by NIHR Exeter Biomedical Research Centre.
- The HyPrevent platform has assembled a deeply phenotyped longitudinal cohort of over 3,600 participants to study how hypertension during pregnancy affects the heart, brain, and blood vessels across the life course. - Researchers developed a unified global organ-damage risk score (HyperScore) and identified distinct disease progression pathways (HyperTrajectories) linked to mortality and advanced organ damage. - The Lapidaire Group investigates postpartum brain and microvascular changes using multimodal imaging and a novel portable device (VITA) to detect early cerebrovascular and microvascular alterations. - Findings aim to inform better prevention and management strategies, with integration into a clinical postnatal hypertension service and the ongoing FLOWER study at Oxford University Hospitals.
- A first-in-human study confirms high-intensity focused ultrasound (HIFU) can safely block abnormal placental blood vessels in early-onset twin-to-twin transfusion syndrome (TTTS). - The non-invasive procedure successfully blocked blood flow in 90% of treated vessels with no adverse side effects, though half of the 10 participants required further treatment. - Researchers are now planning a larger trial of 50 to 100 women to determine whether HIFU can stabilize or reverse TTTS as an alternative to invasive laser therapy. - TTTS affects 10–15% of identical twins sharing a placenta, representing approximately 300–400 pregnancies annually in the UK, with potentially fatal outcomes if untreated.
- The Medical Research Council (MRC) is investing £9.7 million to establish ten Regional Accounts for Clinical Researchers (RACR) across the UK. - The initiative brings together more than 50 research organisations and over 60 NHS organisations across England, Scotland, Wales and Northern Ireland. - The programme will deliver flexible, tailored support to more than 190 clinicians at critical career "pinch points" over the next two years. - The University of Exeter and Royal Devon University Healthcare NHS Foundation Trust will join the Great Western Clinical Research Alliance to support clinical academics.
- University of Oxford researchers gain MRC funding and access to the DAWN supercomputer to develop AI-designed personalised mRNA cancer vaccines through the UK Cancer Vaccine AI & Supercomputing Project. - Cancer Research UK increases annual investment in its Manchester Institute by £6 million, bringing total funding to over £17 million, to expand immunology, immunotherapy, and AI-powered cancer research. - The Oxford-led consortium, now over 2,500 members, uses the CIARA AI scientist platform to analyse tumour biology and predict vaccine targets capable of generating strong anti-cancer immune responses. - The Manchester funding will create up to 100 new research jobs and support studies into how inflammation, the gut microbiome, and lab-grown white blood cells influence cancer treatment outcomes.
- A transatlantic collaboration between the University of Calgary and the Doherty Institute aims to standardize human lung and gut organoid protocols to improve clinical trial success rates. - UK scientists at Cambridge will build a library of standardized, validated organoids from NHS patient cells, funded by a £20 million Medical Research Council grant. - More than 90% of drugs that pass animal testing fail in human trials, underscoring the urgent need for more predictive human-relevant models. - Standardized organoid platforms could enable rapid deployment during future pandemics and advance personalized medicine by identifying patient-specific treatment responses.
- The TOPaZ trial followed 350 adults with osteogenesis imperfecta over eight years and found bone density–increasing drugs did not reduce fracture risk compared to standard care. - Fracture rates were nearly identical: 37% in the treatment group versus 36% in the standard care group, challenging decades of clinical practice. - Experts now call for a shift toward therapies that improve bone quality by targeting collagen defects rather than simply increasing bone density. - The findings set a new benchmark for OI research and underscore the need for disease-specific evidence rather than extrapolating from osteoporosis treatment paradigms.
- The Institute of Cancer Research, London, has developed OPTIMISE-ROR, the first foundational guidance for incorporating patient-reported outcomes into early phase dose-finding cancer trials. - The international consensus-based recommendations address six core areas focusing on treatment tolerability, side effect impact, and quality of life assessment across dose levels. - The guidelines aim to improve clinical interpretation of patient experience data and enhance decision-making for dose escalation and optimization in cancer drug development. - Published in the Journal of Clinical Oncology, the work addresses a critical gap where many early phase trials lack clear standards for defining patient-reported outcome objectives.
- A 73-year-old man in Scotland became the world's first patient to receive gene therapy during heart bypass surgery, marking a breakthrough in cardiovascular treatment. - The PROTECT trial delivers TIMP-3 gene therapy directly to vein grafts during surgery to prevent vessel thickening and blockages that commonly cause bypass failure. - The innovative ex vivo treatment approach uses viral vectors to strengthen grafted vessels before implantation, potentially extending bypass durability beyond current standards. - This pioneering study represents over 20 years of translational research and opens new possibilities for gene therapy applications in cardiovascular medicine.
- Clinical trial applications in the UK increased 9% between January and November 2025, with healthy volunteer studies up 16% and first-in-human trials rising 5%. - The Medical Research Council announced a £50 million Centre of Research Excellence in Clinical Trial Innovation to transform trial design and accelerate patient access to treatments. - New regulatory reforms taking effect in April will introduce fast-track routes for 20% of studies and 14-day assessments for phase 1 trials, aiming to cut setup times from 250 to 150 days. - Companies are seeking more regulatory guidance, with MHRA scientific advice meetings increasing 75% as sponsors work to design trials correctly from the outset.
